A Phase IIa study of tisotumab vedotin (HuMax (R)-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer: updated safety and efficacy.
Authors
Concin, NVergote, I
Dean, Emma J
Lassen, U
De Bono, J
Drew, Y
Machiels, J
Nielsen, D
Arkenau, T
Forster, M
Jones, R
Slomovitz, B
Spicer, J
Cornez, N
Gennigens, C
Fulton, B
Rangwala, R
Coleman, R
Hong, D
Affiliation
University Hospital Leuven, Oncology, Leuven, Belgium;Issue Date
2017